<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bekdash R</submitter><funding>Irving Medical Center, Columbia University</funding><pagination>e3002522</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10939250</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>22(3)</volume><pubmed_abstract>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected approximately 800 million people since the start of the Coronavirus Disease 2019 (COVID-19) pandemic. Because of the high rate of mutagenesis in SARS-CoV-2, it is difficult to develop a sustainable approach for prevention and treatment. The Envelope (E) protein is highly conserved among human coronaviruses. Previous studies reported that SARS-CoV-1 E deficiency reduced viral propagation, suggesting that E inhibition might be an effective therapeutic strategy for SARS-CoV-2. Here, we report inhibitory peptides against SARS-CoV-2 E protein named iPep-SARS2-E. Leveraging E-induced alterations in proton homeostasis and NFAT/AP-1 pathway in mammalian cells, we developed screening platforms to design and optimize the pepti</pubmed_abstract><journal>PLoS biology</journal><pubmed_title>Developing inhibitory peptides against SARS-CoV-2 envelope protein.</pubmed_title><pmcid>PMC10939250</pmcid><funding_grant_id>TRx award program</funding_grant_id><funding_grant_id>Dean’s Office Fund</funding_grant_id><pubmed_authors>Ho DD</pubmed_authors><pubmed_authors>Nair MS</pubmed_authors><pubmed_authors>Huang Y</pubmed_authors><pubmed_authors>Yazawa M</pubmed_authors><pubmed_authors>Tsai HY</pubmed_authors><pubmed_authors>Ahdout J</pubmed_authors><pubmed_authors>Bekdash R</pubmed_authors><pubmed_authors>Yoshida K</pubmed_authors><pubmed_authors>Qiu L</pubmed_authors><pubmed_authors>Uryu K</pubmed_authors><pubmed_authors>Soni RK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Developing inhibitory peptides against SARS-CoV-2 envelope protein.</name><description>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected approximately 800 million people since the start of the Coronavirus Disease 2019 (COVID-19) pandemic. Because of the high rate of mutagenesis in SARS-CoV-2, it is difficult to develop a sustainable approach for prevention and treatment. The Envelope (E) protein is highly conserved among human coronaviruses. Previous studies reported that SARS-CoV-1 E deficiency reduced viral propagation, suggesting that E inhibition might be an effective therapeutic strategy for SARS-CoV-2. Here, we report inhibitory peptides against SARS-CoV-2 E protein named iPep-SARS2-E. Leveraging E-induced alterations in proton homeostasis and NFAT/AP-1 pathway in mammalian cells, we developed screening platforms to design and optimize the pepti</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2026-07-15T07:38:10.609Z</modification><creation>2026-07-01T03:07:38.639Z</creation></dates><accession>S-EPMC10939250</accession><cross_references><pubmed>38483887</pubmed><doi>10.1371/journal.pbio.3002522</doi></cross_references></HashMap>